江苏鱼跃医疗设备股份有限公司 独立董事专门会议 2024 年第一次会议决议 一、独立董事专门会议召开情况 2024 年 4 月 19 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"） 以通讯表决的方式召开了独立董事专门会议 2024 年第一次会议。公司于 2024 年 4 月 16 日以书面送达及电子邮件方式发出了召开公司独立董事专门会议 2024 年 第一次会议的通知以及提交审议的议案。全体独立董事共同推举公司独立董事于 春女士任本次会议的召集人并主持本次会议，会议应出席独立董事 3 名，实际出 席会议独立董事 3 名。本次会议的召集、召开及表决等程序符合《中华人民共和 国公司法》和《公司章程》的有关规定，会议决议合法、有效。会议由召集人于 春女士主持，经与会独立董事充分讨论，审议通过了如下议案： 二、独立董事专门会议审议情况 1、关于《公司 2024 年度日常关联交易预计》的议案 满足公司日常经营活动的需要，将遵守公平、公正、公开的原则，按照市场情况 协商确定价格，关联交易定价政策及依据公允，不存在损害公司及投资者利益的 情形。 独立董事专门会议同意本次公司与关联方的日常关联交易预计事项并同意 提交公 ...

江苏鱼跃医疗设备股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 3 | | 信念中和合分析 官 名 所 上 豆 可 东城 期 北 下 街 版 北 下 街 版 北 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, No.8, Chaoyangmen Beidajie, | | | +86 (010) 6554 7190 | Dongcheng District, Beijing, I | 传真: | | certified public accountants 100027, P.R.China | | facsimile: +86 (010) 6554 7190 | 关于江苏鱼跃医疗设备股份有限公司 XYZH/2024SHAA1F0047 江苏鱼跃医 ...

机构名称：信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"） 江苏鱼跃医疗设备股份有限公司 2023 年度会计师事务所履职情况评估报告暨 审计委员会履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独立董 事管理办法》《上市公司治理准则》《国有企业、上市公司选聘会计师事务所管理 办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》及《江苏鱼跃医疗设备股份有限公司章程》等相关规定，现将江苏鱼跃医疗 设备股份有限公司（以下简称"公司"）2023 年度会计师事务所履职情况和审计 委员会履行监督职责的情况汇报如下： 一、2023 年度会计师事务所基本情况 （一）会计师事务所基本情况 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 截止 2023 年 12 月 31 日，信永中和合伙人（股东）245 人，注册会计师 1,656 人，签署过证券服务业务审计报告的注册会计师人数超过 660 人。 （二）聘任会计师事务所履行的程序 2023 年 ...

江苏鱼跃医疗设备股份有限公司 江苏鱼跃医疗设备股份有限公司 江苏鱼跃医疗设备股份有限公司全体股东： 2023 年度 审计报告 审计报告 XYZH/2024SHAA1B0079 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-4 | | 公司财务报告 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并所有者权益变动表 | 9-10 | | — | 母公司所有者权益变动表 | 11-12 | | — | 财务报表附注 | 13-136 | 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反 映了鱼跃医疗公司 2023 年 12 月 31 日的合并及母公司财务状况以及 2023 年度的合并及 母公司经营成果和现金流量。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册会计 师对财务报 ...

江苏鱼跃医疗设备股份有限公司 2023 年度 内部控制审计报告 一、 企业对内部控制的责任 按照《企业内部控制基本规范》 、《企业内部控制应用指引》 、《企业内部控制评 价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是鱼跃医疗公司董事 会的责任。 二、 注册会计师的责任 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-2 | | 公司内部控制自我评价报告 | 1-9 | 内部控制审计报告 XYZH/2024SHAA1B0080 江苏鱼跃医疗设备股份有限公司 江苏鱼跃医疗设备股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计 了江苏鱼跃医疗设备股份有限公司（以下简称鱼跃医疗公司）2023 年 12 月 31 日财务报 告内部控制的有效性。 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降 ...

本人万遂人，作为江苏鱼跃医疗设备股份有限公司（以下简称"公司"）第五届董 事会、第六届董事会独立董事，任期内本人严格按照《中华人民共和国公司法》（以下 简称"《公司法》"）《上市公司独立董事管理办法》等法律法规规定及《公司章程》 《公司独立董事制度》《公司独立董事年报工作制度》《公司独立董事专门会议制度》 的要求，忠实履行职责，充分发挥独立董事的作用，勤勉尽责，维护了公司整体利益， 维护了全体股东尤其是中小股东的合法权益。现将2023年度履行独立董事职责情况汇报 如下： 江苏鱼跃医疗设备股份有限公司 独立董事2023年度述职报告 万遂人 2023 年公司以现场投票与网络投票相结合的方式分别于 5 月 18 日、9 月 28 日、11 月 24 日共召开了 3 次股东大会，本人出席了 3 次股东大会。 3、董事会专门委员会履职情况 （1）本人作为第五届董事会、第六届董事会薪酬与考核委员会主任委员，积极组 织薪酬与考核委员会会议，对2022年董事、高级管理人员的工作业绩进行了客观、公正 的考核，同时也对2023年董事、高级管理人员的工作业绩提出期望，提高了公司管理层 的积极性。 一、 基本情况 本人万遂人，195 ...

Financial Performance - The company's operating revenue for 2023 reached ¥7,971,734,452.47, representing a 12.25% increase from ¥7,101,679,159.74 in 2022[13]. - Net profit attributable to shareholders for 2023 was ¥2,395,853,276.49, a significant increase of 50.21% compared to ¥1,595,037,435.14 in 2022[13]. - The net profit after deducting non-recurring gains and losses was ¥1,835,621,624.25, up 46.79% from ¥1,250,509,076.10 in the previous year[13]. - The basic earnings per share for 2023 was ¥2.41, reflecting a 49.69% increase from ¥1.61 in 2022[13]. - The total assets at the end of 2023 amounted to ¥15,967,458,083.34, which is a 5.78% increase from ¥15,095,211,328.39 at the end of 2022[13]. - The net assets attributable to shareholders increased by 19.31% to ¥11,763,562,138.83 from ¥9,860,018,658.01 in 2022[13]. - The company reported a net cash flow from operating activities of ¥2,126,977,841.98, a decrease of 7.72% compared to ¥2,304,919,408.76 in 2022[13]. - The company achieved total revenue of 7.97 billion yuan in 2023, representing a year-on-year growth of 12.25%[37]. - The net profit attributable to shareholders reached 2.40 billion yuan, an increase of 50.21% compared to the previous year[37]. - The cash flow from operating activities was 2.13 billion yuan, a decrease of 7.72% year-on-year, while accounts receivable decreased by 30.70%[37]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[2]. - The profit distribution plan for 2023 proposes a cash dividend of 8.00 yuan per 10 shares, totaling approximately 801.6 million yuan, which represents 33.46% of the net profit attributable to shareholders[87]. - The total cash dividend amount is fully covered by the company's distributable profits, with no other forms of cash distribution planned[127]. Governance and Compliance - The financial report has been confirmed as true, accurate, and complete by the company's responsible persons and accounting heads[2]. - All board members attended the meeting to review the annual report, ensuring collective responsibility for its content[2]. - The company has a comprehensive governance structure in place, as detailed in the governance section of the report[4]. - The company is committed to enhancing its governance and operational standards, ensuring compliance with relevant laws and regulations[88]. - The company has established internal control systems for foreign exchange hedging to ensure compliance with legal requirements and protect shareholder interests[65]. - The company has established a dedicated meeting system for independent directors to enhance governance[140]. Market and Industry Outlook - Jiangsu Yuyue Medical Equipment Co., Ltd. is positioned in the rapidly growing Chinese medical device market, which is the second largest globally, driven by factors such as GDP growth and an aging population[22]. - The medical device industry in China is expected to grow significantly due to factors such as GDP growth, rising consumer spending, and an aging population[72]. - The industry is undergoing consolidation, with increasing market concentration as regulations tighten and support for leading domestic companies is emphasized[72]. - The overall demand for medical devices is less affected by macroeconomic conditions, indicating a stable growth trajectory for the industry[22]. Research and Development - The company invested 5.04 billion yuan in R&D, accounting for 6.33% of total revenue, while total expenses increased by only 0.23%[39]. - The company is committed to increasing R&D investment to drive innovation and product upgrades, ensuring high-quality medical products and services to meet growing market demands[78]. - The company is expanding its product line with multiple new glucose monitoring devices, enhancing market competitiveness[52]. - The company is developing a new high-flow humidification therapy device for hospital use, which is currently in R&D[51]. - The company has a total of 1,031 R&D personnel in 2023, a decrease of 9.32% from 1,137 in 2022[53]. Strategic Initiatives - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the coming years[12]. - The company is focusing on three core business areas: respiratory therapy, diabetes care, and infection control, while actively incubating high-potential businesses such as emergency care and ophthalmology[74]. - The company aims to expand its international market presence by tailoring its medical device offerings to the specific needs of different countries and regions, leveraging strategic partnerships to enhance competitiveness[76]. - The company is enhancing its marketing strategies to improve online market share and operational efficiency, focusing on both online and offline channels to boost sales performance[76]. Risk Management - The management discussed potential risks and challenges faced by the company in the industry, emphasizing the importance of investor awareness regarding investment risks[2]. - The company recognizes the importance of risk management and will strengthen its internal risk control systems to address potential challenges arising from regulatory compliance and operational processes[78]. Employee and Management Structure - The total number of employees at the end of the reporting period is 6,114, with 2,735 in the parent company and 3,379 in major subsidiaries[118][119]. - The company emphasizes a performance culture that links total compensation to job value and performance, aiming to attract and retain talent[122]. - The company has a structured management system with independent personnel files and compensation systems, separate from the controlling shareholder[90]. - The company is dedicated to talent development, building a high-quality R&D team to foster innovation and maintain competitive advantages in the medical device sector[77]. Environmental and Social Responsibility - The report highlights the company's commitment to environmental and social responsibilities[5]. - The company donated thousands of medical-grade oxygen machines to rural healthcare institutions in impoverished areas, supporting social responsibility initiatives[144]. - The company has implemented a smart energy management system to reduce energy consumption and enhance resource utilization, contributing to its "dual carbon" strategy[142]. Financial Stability and Investments - The company has maintained a strong financial position, with a current ratio of 2.5, indicating good liquidity and financial health[103]. - The company has entrusted RMB 2.935 billion in bank financial products, with no overdue amounts or impairment provisions reported[164]. - The company has completed the acquisition of 100% equity in Beai Ni Environmental Technology (Shanghai) Co., Ltd., which is now included in the consolidated financial statements[135].

1 2023 可持续发展报告 目录 CONTENTS | | | 47 环境友好 加速绿色低碳转型 | 29 | 创新引领 让科技律动生命 | 59 | 以人为本 成就生命价值 | | --- | --- | --- | --- | | 31 | 创新驱动未来 | 61 | 携手员工成长 | | 34 | 深耕智慧医疗 | 75 | 守护生命健康 | | 38 | 坚守品质初心 | | | 强化公司治理 11 恪守商业道德 14 全链协同管理 17 可持续供应链 21 信息安全与隐私保护 26 完善环境管理 49 绿色产品设计 51 应对气候变化 52 降低环境影响 56 81 关键绩效表 85 报告编制说明 86 指标索引表 江苏鱼跃医疗设备股份有限公司 2023 可持续发展报告 董事长致辞 时序更替，华章日新。2023 年对于鱼跃医疗而言意义 非凡，随着人们生活水平提升和人口老龄化加剧，医疗 健康需求和品质要求持续快速增长；随着产业加速变 革，绿色化、数智化发展水平显著提高，我们将 ESG 理念深度融入经营发展之中，全面加强研发创新，深 入推进数智转型，持续提升产品可及性，这一年深耕 与突破并行，提质与增 ...

江苏鱼跃医疗设备股份有限公司 2023 年度监事会工作报告 一、监事会工作情况 报告期内，江苏鱼跃医疗设备股份有限公司（以下简称"公司"）第五届监 事会、第六届监事会成员，在各自任职期间均认真履行职责，恪尽职守，为公司 规范运行提供了连续的监督和保障。2023 年公司第五届监事会共召开了监事会 会议 7 次，第六届监事会共召开了监事会会议 1 次，具体情况如下： （一）第五届监事会第六次会议 公司于 2023 年 4 月 18 日以书面送达及传真方式向公司全体监事发出了召 开公司第五届监事会第六次会议的通知，经全体监事一致同意，豁免本次监事会 的通知时限。会议于 2023 年 4 月 27 日以通讯表决的方式召开，会议应到监事 7 名，实到监事 7 名。本次会议的召集、召开符合《中华人民共和国公司法》和《公 司章程》的有关规定，会议决议合法、有效。会议由公司监事会主席吕英芳先生 主持，经与会监事充分讨论，审议通过了如下议案： 1、关于《公司 2022 年度监事会工作报告》的议案 表决结果：同意：7 票；反对：0 票；弃权：0 票 本议案需提交2022年度股东大会审议。 2、关于《公司 2022 年度财务决算报 ...

Financial Performance - Revenue for the first quarter of 2024 was RMB 2,231,209,294.86, a decrease of 17.44% compared to the same period last year[3] - Net profit attributable to shareholders of the listed company was RMB 659,412,768.43, a decrease of 7.58% year-on-year[3] - Total operating income decreased to 2,231,209,294.86 RMB, down by 17.44% year-over-year[15] - Operating profit for the first quarter of 2024 was RMB 777.03 million, a decrease from RMB 865.19 million in the same period last year[16] - Net profit attributable to the parent company's owners was RMB 659.41 million, compared to RMB 713.52 million in the previous year[16] - The company's total comprehensive income for the quarter was RMB 658.07 million, compared to RMB 708.00 million in the same period last year[16] - Basic earnings per share for the quarter were RMB 0.6619, down from RMB 0.7186 in the same period last year[16] Cash Flow - Net cash flow from operating activities was RMB 675,553,263.28, down 17.14% compared to the same period last year[3] - Cash flow from operating activities was RMB 675.55 million, down from RMB 815.33 million in the prior year[17] - Cash flow from investing activities showed a net outflow of RMB 28.30 million, an improvement from a net outflow of RMB 1.55 billion in the previous year[17] - Cash flow from financing activities had a net outflow of RMB 199.52 million, compared to a net outflow of RMB 370.68 million in the same period last year[18] - Total cash and cash equivalents at the end of the period were RMB 7.64 billion, up from RMB 3.64 billion in the previous year[18] - Net cash flow from investment activities increased by 98.18% year-on-year, mainly due to the company's investment in Chongqing Ant Consumer Finance Co., Ltd. and the purchase of structured deposits in the same period last year[7] Assets and Liabilities - Total assets at the end of the reporting period were RMB 16,599,651,823.63, an increase of 3.96% compared to the end of the previous year[3] - Total assets increased to 16,599,651,823.63 RMB, up by 3.96% compared to the previous period[13] - Total current assets at the end of the period amount to 10,078,070,805.88 RMB, up from 9,385,155,178.47 RMB at the beginning of the period[12] - Long-term receivables at the end of the period are 654,332,861.49 RMB, unchanged from the beginning of the period[12] - Total liabilities decreased to 4,013,294,011.01 RMB, down by 0.95% compared to the previous period[13] - Total equity increased to 12,586,357,812.62 RMB, up by 5.63% compared to the previous period[14] Accounts Receivable and Inventory - Accounts receivable at the end of the reporting period increased by 97.39% compared to the beginning of the period, mainly due to an increase in reasonable receivables within the credit period generated by normal business activities[6] - Accounts receivable at the end of the period amount to 884,734,318.76 RMB, up from 448,210,952.92 RMB at the beginning of the period[12] - Inventory at the end of the period is 1,197,429,569.07 RMB, down from 1,412,311,882.61 RMB at the beginning of the period[12] Income and Expenses - Other income increased by 512.00% year-on-year, mainly due to an increase in government subsidies received during the reporting period[6] - Financial expenses decreased by 4519.01% year-on-year, mainly due to an increase in interest income from bank time deposits and a decrease in loan interest expenses[6] - Cash received from tax refunds increased by 58.14% year-on-year, mainly due to an increase in export tax refunds from export business[6] - Operating costs decreased to 1,584,225,003.71 RMB, down by 14.26% compared to the previous year[15] - R&D expenses decreased to 124,450,232.82 RMB, down by 7.97% year-over-year[15] - Financial expenses showed a net income of 50,842,630.47 RMB, primarily due to higher interest income[15] - Other income increased significantly to 156,252,340.07 RMB, up by 511.89% year-over-year[15] - Credit impairment losses increased to -25,356,963.05 RMB, up by 65.68% compared to the previous year[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 53,675[8] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of the shares, totaling 245,983,450 shares[8] - Wu Guangming, an individual shareholder, holds 10.32% of the shares, totaling 103,438,537 shares[8] - Wu Qun, another individual shareholder, holds 7.72% of the shares, totaling 77,389,840 shares, with 58,042,380 shares under restricted sale conditions[8] - Hong Kong Securities Clearing Company Ltd. holds 3.52% of the shares, totaling 35,239,310 shares[8] Monetary Funds and Exchange Rate Impact - The total monetary funds at the end of the period amount to 7,648,128,210.89 RMB, an increase from 7,215,419,322.83 RMB at the beginning of the period[12] - The impact of exchange rate changes on cash and cash equivalents increased by 104.24% year-on-year, mainly due to fluctuations in the US dollar exchange rate during the reporting period[7] Sales and Payments - Sales revenue from goods and services was RMB 2.02 billion, a decrease from RMB 2.66 billion in the previous year[17] - Payments for goods and services were RMB 675.39 million, down from RMB 768.02 million in the prior year[17]